One Registration or Several: Manufacturing Sites in Guatemala
Updated: 2026-11-11 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
Whether the same product manufactured at different plants can share a registration number in Guatemala depends on whether the manufacturer is the same entity: Article 6.12 of NT 37 Versión 5-2016 provides that where a product is manufactured by the same manufacturer at different production sites while maintaining the same packaging and labelling, it may be handled as an «Adición de una planta alterna de fabricación» — the addition of an alternative manufacturing plant — and the same sanitary registration number continues to apply. Where the manufacturers themselves are different, that is, different legal entities, separate registrations are required. The dividing line is therefore the identity of the corporate entity behind the product, not the geographic location of the plant or the country in which production takes place. Multi-site manufacturers should establish this entity-level fact at the very start of the project, because it determines the entire procedural architecture: one registration with an added alternative plant on the one hand, or a portfolio of parallel registrations on the other, each with its own dossier, fee schedule and renewal calendar.
2. Legal basis
The alternative plant mechanism is supported by the following provisions.
| Document | Provision | Content |
| NT 37, Versión 5-2016 (2016-02-22) | Article 6.12 | «Adición de una planta alterna de fabricación»: where the same manufacturer manufactures at different production sites with the same packaging and labelling, the same sanitary registration number is granted for marketing |
| NT 37, Versión 5-2016 | Article 6.12.2 | A sworn declaration of the legal representative must be submitted, stating that the product formulation, packaging and labelling are identical |
| NT 37, Versión 5-2016 | Article 6.12.6 | A certificate of manufacturing guarantee issued by the health authority must be submitted (BPM, standards approval, ISO certificate, FDA, DGKC or IFCC) |
| NT 37, Versión 5-2016 | Article 5.1.7 | A certified copy of the manufacturer’s power of attorney must be submitted |
| NT 40, Versión 3-2015 | Article 7 | On the reagent side, the same two authorisation-type changes exist: «Cambio de titular de fabricación» and «Adición de una planta alterna de fabricación» |
Article 6.12 requires six items of documentation: 6.12.1 the change application form (signed and stamped by the responsible professional); 6.12.2 the sworn declaration of the legal representative; 6.12.3 the proof of payment of the fee; 6.12.4 the original packaging or a legible specimen; 6.12.5 the original registration certificate or a signed statement that it has not been submitted; and 6.12.6 the certificate of manufacturing guarantee.
3. Expert insights
Insight one: Article 6.12 is an expand-capacity, keep-the-number pathway, and external sources often describe it backwards. A considerable amount of industry material claims that the same product manufactured in different countries must be registered separately. The actual wording of the official Article 6.12 is the opposite in the defined scenario: the same manufacturer, different production sites, identical packaging and labelling — the same registration number is granted. The true dividing line is «whether the manufacturer is the same entity», not «whether the plants are in the same country».
Insight two: the three conditions must be satisfied simultaneously. The same manufacturer, different production sites, and identical packaging and labelling — not one of the three can be missing. Article 6.12.2 requires a sworn declaration from the legal representative precisely to confirm the «misma fórmula, presentación y etiquetado», that is, the same formulation, presentation and labelling. Once the new plant’s product differs in packaging or labelling in any respect, the Article 6.12 route is closed and the change must proceed under the corresponding provisions for modified presentations.
Insight three: the new plant still requires a certificate of manufacturing guarantee. Article 6.12.6 requires a certificate of manufacturing guarantee issued by a health authority for the new plant, in an acceptable form that includes BPM, standards approval, ISO certificates, FDA, DGKC or IFCC. This shows that «continuing the registration number» does not mean «exemption from scrutiny of the new plant»; the quality of the additional site is assessed in its own right, and the mechanism only spares the company the administrative burden of opening a new registration number.
Insight four: the two types of change on the reagent side must be distinguished. Article 7 of NT-40 lists both the «Cambio de titular de fabricación», a change of manufacturing entity, and the «Adición de una planta alterna de fabricación», the addition of an alternative plant. Both are authorisation-type changes that require approval rather than mere notification. Selecting the wrong category results in the change not being accepted, and the application then has to be withdrawn and refiled under the correct heading, losing time in the process.
4. Practical recommendations
- For multi-plant projects, first determine whether the manufacturer is the same legal entity: the same entity proceeds by adding an alternative plant under Article 6.12, while different entities register separately.
- Before using Article 6.12, confirm that all three conditions are met and prepare the sworn declaration of the legal representative in advance.
- Obtain a certificate of manufacturing guarantee for the new plant, selecting an acceptable issuing form under Article 6.12.6.
- Where there is any difference in packaging or labelling, do not use Article 6.12; instead handle the matter under Articles 6.10 or 6.11.
- For reagent projects, distinguish between a change of manufacturing entity and the addition of an alternative plant, filing both as authorisation-type changes.
5. Verification checklist
- □ It has been confirmed whether the plants belong to the same manufacturer
- □ In the same-manufacturer case, the three conditions have been checked (same entity, different sites, same packaging and labelling)
- □ The sworn declaration of the legal representative has been prepared under Article 6.12.2
- □ The certificate of manufacturing guarantee for the new plant has been prepared under Article 6.12.6
- □ Any packaging or labelling difference has triggered a switch of procedure
- □ The correct change category has been selected for reagent projects
Regulatory information verified as of 29 October 2026.
How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Guatemalan market. Our team manages Ministry of Public Health and Social Assistance (MSPAS) registrations, coordinates import and distributor requirements, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us